Not provided
long-acting cabotegravir coadministered with recombinant human hyaluronidase PH20 (rHuPH20)
Not provided
Not provided
Not provided
Unknown
Unknown
Subcutaneous, Intramuscular, To be determined
Aqueous drug particle suspension
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cabotegravir 4-monthly (Q4M)
Cabotegravir Stearate (M2CAB)
Cabotegravir and Rilpivirine
cabotegravir PH20
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL
There are no publication
No documents were uploaded
There are no additional links
Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology
Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit
In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing